Skip to content

Residual Gastric Content and GLP-1

Residual Gastric Content and GLP-1

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06814080
Enrollment
45
Registered
2025-02-07
Start date
2025-05-22
Completion date
2026-08-31
Last updated
2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-op Gastric Emptying

Brief summary

Studies have shown that even following the fasting guideline, patients on GLP-1 still have residual gastric content which increases their risk of aspiration during anesthesia. We aim to investigate the prevalence of full stomachs following different fasting times.

Detailed description

Glucagon-like peptide-1 (GLP-1) receptor agonists have become increasingly popular as both diabetic and weight loss therapies. One effect of this class of medication is delayed gastric emptying, which may impact the risk of aspiration during anesthesia delivery. Some of them have a very long half-life of approximately one week. Thus, it takes approximately five weeks to achieve its steady-state concentration, and just as long for its effects to terminate after stopping the drug. As a standard of care, patients are allowed to drink up to 2 hours and to eat up to 8 hours before surgery. Studies have shown that even following the fasting guideline, patients still have residual gastric content which increases their risk of aspiration during anesthesia. Since stopping these drugs for a long time is not practical as it is going to disrupt their glycemic control and reverse the weight loss, we propose to test extending the fasting time. We aim to investigate the prevalence of full stomachs following different fasting times. patients will be assigned to one of three groups: Group 1(G1) with 8-hour fasting, Group 2 (G2) with 10-hour fasting, and Group 3 (G3) groups with 12-hour fasting

Interventions

None listed

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Age ≥ 18 yr. ASA physical status I- III Elective surgery

Exclusion criteria

* Pregnancy * History of upper gastrointestinal disease or previous surgery on the esophagus, stomach or upper abdomen; * Documented abnormalities of the upper gastrointestinal tract such as gastric tumors; recent upper gastrointestinal bleeding (within the preceding 1 month). * Medicines that may delay gastric emptying (e.g., anticholinergic agents, opioid) * ASA class IV or above * Unable to understand English * Cardiac cases with low ejection fraction * Elderly patients above 65 years of age * Liver or renal transplant cases * Type 1 diabetes Patients on insulin or sulphonylurea medication

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of full stomach or residual gastric content in the 3 groups8 hoursEmpty stomach when no content or clear liquids are visibly inferior to 1.5ml/kg. Full stomach includes the visualization of solids on gastric ultrasonography or a volume of clear liquids greater than 1.5ml/kg.

Countries

United States

Contacts

Primary ContactMohamed A Abdeldayem, MD
MAAbdeldayem@uams.edu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026